Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now later-stage tilt small index

Urea Cycle Disorder: later-stage trial registry

3 of 5 indexed Urea Cycle Disorder trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Urea Cycle Disorder: 5 US clinical trials tracked, 3 recruiting.

Urea Cycle Disorder is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 3 of these trials.

Enrollment posture brief

Registry condition urea-cycle-disorder

OPEN 3 | RECR 60% | LATE 1 | EARLY 0 | RANK #3391 | SPON 3

Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Urea Cycle Disorder (this)60%
Open-enrollment share among volume-matched conditions near Urea Cycle Disorder

Urea Cycle Disorder lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Urea Cycle Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Urea Cycle Disorder is recruiting above its size-band peers.

    3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Urea Cycle Disorder research.

    Baylor College of Medicine accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Most Urea Cycle Disorder trials plan to enrol fewer than 100 people.

    Median target enrolment is 27 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.

  4. Urea Cycle Disorder research leans observational.

    2 interventional and 3 observational studies make up this index (40% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 41

Phase Distribution

PhaseTrial count
Phase 4 1

Named interventions

Most-linked intervention names on Urea Cycle Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

RAVICTI Drug
1 trials
Neo-ASA Dietary supplement
1 trials
Placebo Dietary supplement
1 trials

US sites by state

Facility locations filed on Urea Cycle Disorder trials. A trial with sites in several states counts in each.

Texas 3 trials
Washington 2 trials
Pennsylvania 2 trials
Utah 1 trials
Oregon 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Urea Cycle Disorder page

5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urea Cycle Disorder condition card totals 5 registered trials; most-linked intervention RAVICTI; top US site state District of Columbia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.